Hester Biosciences Net Profit Soars Over Two-Fold in December Quarter

• Hester Biosciences reported a net profit of Rs 11 crore for the third quarter ended December 31, 2025, a significant increase from Rs 4 crore in the same period last fiscal.
• Revenue from operations grew by 12 per cent to Rs 70 crore in Q3 FY26, up from Rs 63 crore in the year-ago period.
• The Poultry Healthcare Division achieved 32 per cent growth, driven by improved placements and consistent demand for vaccines.
• The Animal Healthcare Division saw a 38 per cent decline, mainly due to delays in government immunisation programs for ruminants (PPR and Goat Pox).
• Hester Biosciences secured marketing and manufacturing licenses for the H9N2 Avian Influenza vaccine, enhancing its poultry vaccine offerings.

Why It Matters: Hester Biosciences reported strong Q3 FY26 results with profit soaring, driven by poultry segment growth and new vaccine licenses.